{
  "$schema": "folio-library-document/v1",
  "id": "10665-255866",
  "title": "WHO technical brief: preventing HIV during pregnancy and breastfeeding in the context of PrEP",
  "variant": "pdf",
  "pages": 16,
  "tocSource": "outline",
  "tocMethod": null,
  "toc": [
    {
      "level": 1,
      "title": "Introduction",
      "number": null,
      "page": 4,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-000-introduction"
    },
    {
      "level": 1,
      "title": "What is PrEP?",
      "number": null,
      "page": 4,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-001-what-is-prep"
    },
    {
      "level": 1,
      "title": "WHO recommendation on PrEP",
      "number": null,
      "page": 4,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-002-who-recommendation-on-prep"
    },
    {
      "level": 1,
      "title": "Why offer PrEP to pregnant and breastfeeding women?",
      "number": null,
      "page": 5,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-003-why-offer-prep-to-pregnant-and-breastfeeding-wom"
    },
    {
      "level": 1,
      "title": "PrEP safety during pregnancy and breastfeeding",
      "number": null,
      "page": 6,
      "pageLabel": "4",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-004-prep-safety-during-pregnancy-and-breastfeeding"
    },
    {
      "level": 1,
      "title": "Providing PrEP to women who would most benefit",
      "number": null,
      "page": 8,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-005-providing-prep-to-women-who-would-most-benefit"
    },
    {
      "level": 1,
      "title": "PrEP as part of PMTCT in settings of high HIV incidence",
      "number": null,
      "page": 8,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-006-prep-as-part-of-pmtct-in-settings-of-high-hiv-in"
    },
    {
      "level": 1,
      "title": "PrEP for safer conception",
      "number": null,
      "page": 11,
      "pageLabel": "9",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-prep-for-safer-conception"
    },
    {
      "level": 1,
      "title": "Monitoring PrEP use by pregnant and breastfeeding women",
      "number": null,
      "page": 11,
      "pageLabel": "9",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-008-monitoring-prep-use-by-pregnant-and-breastfeedin"
    },
    {
      "level": 2,
      "title": "Summary of issues and considerations",
      "number": null,
      "page": 12,
      "pageLabel": "10",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-009-summary-of-issues-and-considerations"
    },
    {
      "level": 1,
      "title": "Key messages",
      "number": null,
      "page": 12,
      "pageLabel": "10",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-010-key-messages"
    },
    {
      "level": 2,
      "title": "References",
      "number": null,
      "page": 13,
      "pageLabel": "11",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-011-references"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 4,
      "labelStart": "a",
      "labelEnd": "2",
      "words": 1342,
      "summary": {
        "text": "Front matter of the 2017 WHO technical brief on preventing HIV during pregnancy and breastfeeding in the context of PrEP, with title page, copyright and licence terms, acknowledgements and table of contents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "breastfeeding women",
          "heading": false
        },
        {
          "term": "prep",
          "heading": false
        },
        {
          "term": "during pregnancy",
          "heading": false
        },
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "technical brief",
          "heading": false
        },
        {
          "term": "preventing hiv",
          "heading": false
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        }
      ],
      "extract": "PREVENTING HIV DURING PREGNANCY AND BREASTFEEDING IN THE CONTEXT OF PREP JULY 2017 TECHNICAL BRIEF WHO TECHNICAL BRIEF: Preventing HIV during pregnancy and breastfeeding in the context of PrEP WHO/HIV/2017.09 © World Health Organization 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO;",
      "extractCut": true,
      "blocks": [
        "library/10665-255866/blocks/prose-sec-front-matter",
        "library/10665-255866/blocks/figure-img-p001-1"
      ]
    },
    {
      "id": "sec-000-introduction",
      "number": null,
      "title": "Introduction",
      "level": 1,
      "pageStart": 4,
      "pageEnd": 4,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 329,
      "summary": {
        "text": "Introduces the technical brief by explaining that women in high-prevalence settings still acquire HIV during pregnancy and breastfeeding, raising the risk of transmission to infants. It notes established prevention measures and proposes oral PrEP as a complement, then lists the brief's aims.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "breastfeeding women",
          "heading": false
        },
        {
          "term": "offering prep",
          "heading": false
        },
        {
          "term": "during pregnancy",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "incidence settings",
          "heading": false
        },
        {
          "term": "postnatal",
          "heading": false
        },
        {
          "term": "antenatal",
          "heading": false
        }
      ],
      "extract": "In many countries with high-prevalence generalized HIV epidemics, women continue to acquire HIV during pregnancy and breastfeeding. Women who become infected during this time also risk transmitting HIV to their infants. Incident HIV infection during pregnancy and breastfeeding contributes to a significant proportion of infants with HIV in very high incidence settings, and is of public health relevance for antenatal",
      "extractCut": true
    },
    {
      "id": "sec-001-what-is-prep",
      "number": null,
      "title": "What is PrEP?",
      "level": 1,
      "pageStart": 4,
      "pageEnd": 4,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 33,
      "summary": {
        "text": "Defines PrEP as daily oral TDF or TDF/FTC taken to prevent HIV acquisition by HIV-negative people.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "tdf",
          "heading": false
        },
        {
          "term": "ftc",
          "heading": false
        }
      ],
      "extract": "PrEP is the use of daily oral tenofovir disoproxil fumarate (TDF) or co-formulated TDF/emtricitabine (TDF/FTC) to prevent HIV acquisition. PrEP has been shown to be effective in a wide range of HIV-negative populations.",
      "extractCut": false
    },
    {
      "id": "sec-002-who-recommendation-on-prep",
      "number": null,
      "title": "WHO recommendation on PrEP",
      "level": 1,
      "pageStart": 4,
      "pageEnd": 5,
      "labelStart": "2",
      "labelEnd": "3",
      "words": 378,
      "summary": {
        "text": "Outlines WHO's 2015 recommendation that oral TDF-containing PrEP be offered to people at substantial HIV risk and how the 2016 consolidated guidelines addressed its use in pregnancy and breastfeeding. It notes that the benefits of preventing maternal HIV and mother-to-child transmission were judged to outweigh potential risks of fetal and infant drug exposure.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "prep during",
          "heading": false
        },
        {
          "term": "breastfeeding women",
          "heading": false
        },
        {
          "term": "containing tdf",
          "heading": false
        },
        {
          "term": "recommendation",
          "heading": true
        },
        {
          "term": "continuing substantial",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        }
      ],
      "extract": "In 2015, the World Health Organization (WHO) recommended that oral PrEP containing TDF be offered as an additional prevention choice for people at substantial risk1 of HIV infection, as part of combination HIV prevention approaches (1). This recommendation was based on a systematic review and meta-analysis (2) of high-quality evidence on PrEP’s effectiveness from clinical trial research. WHO included this",
      "extractCut": true
    },
    {
      "id": "sec-003-why-offer-prep-to-pregnant-and-breastfeeding-wom",
      "number": null,
      "title": "Why offer PrEP to pregnant and breastfeeding women?",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 6,
      "labelStart": "3",
      "labelEnd": "4",
      "words": 266,
      "summary": {
        "text": "Explains why pregnant and breastfeeding women in high-incidence settings face increased HIV risk, with a figure listing biological and behavioural factors. It also summarises WHO recommendations on antenatal HIV testing, retesting and partner testing as part of prevention.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "breastfeeding women",
          "heading": true
        },
        {
          "term": "cervical inflammation",
          "heading": false
        },
        {
          "term": "during pregnancy",
          "heading": false
        },
        {
          "term": "pregnant",
          "heading": true
        },
        {
          "term": "hiv infection",
          "heading": false
        },
        {
          "term": "postpartum period",
          "heading": false
        },
        {
          "term": "increased risk",
          "heading": false
        },
        {
          "term": "prep",
          "heading": true
        }
      ],
      "extract": "Pregnant and breastfeeding women living in settings where HIV incidence is greater than three per 100 person–years, particularly in sub-Saharan Africa, often remain at substantial and increased risk of HIV acquisition during pregnancy and breastfeeding. Biological factors increase susceptibility, and social and behavioural factors may increase exposure to HIV infection (Figure 1). Pregnant and breastfeeding women",
      "extractCut": true
    },
    {
      "id": "sec-004-prep-safety-during-pregnancy-and-breastfeeding",
      "number": null,
      "title": "PrEP safety during pregnancy and breastfeeding",
      "level": 1,
      "pageStart": 6,
      "pageEnd": 8,
      "labelStart": "4",
      "labelEnd": "6",
      "words": 1190,
      "summary": {
        "text": "Reviews evidence on the safety of PrEP during pregnancy and breastfeeding, drawing on a 2016 WHO systematic review of TDF use in HIV-positive and HIV-negative women. It reports that few adverse pregnancy, birth or infant outcomes were linked to TDF, and discusses data on drug levels in breast milk and infant bone and renal effects. It concludes that PrEP can be used in pregnancy and breastfeeding and as part of safer conception.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "during pregnancy",
          "heading": true
        },
        {
          "term": "during breastfeeding",
          "heading": true
        },
        {
          "term": "tdf ftc",
          "heading": false
        },
        {
          "term": "tdf art",
          "heading": false
        },
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "receiving tdf",
          "heading": false
        },
        {
          "term": "tdf-containing art",
          "heading": false
        },
        {
          "term": "hiv-negative women",
          "heading": false
        }
      ],
      "extract": "The 2016 WHO guidelines state that there is no safety-related rationale for disallowing or discontinuing PrEP use during pregnancy and breastfeeding for HIV-negative women who are receiving PrEP and remain at risk of HIV acquisition (1). The guidelines conclude that in such situations the benefits of preventing HIV acquisition in the mother, and the accompanying reduced risk of mother-to-child HIV transmission",
      "extractCut": true
    },
    {
      "id": "sec-005-providing-prep-to-women-who-would-most-benefit",
      "number": null,
      "title": "Providing PrEP to women who would most benefit",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 8,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 139,
      "summary": {
        "text": "Describes three situations in which HIV-negative pregnant or breastfeeding women may be offered PrEP, together with testing, adherence counselling, monitoring and other prevention options.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "woman",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "substantial risk",
          "heading": false
        },
        {
          "term": "women",
          "heading": true
        }
      ],
      "extract": "Although there is limited experience with the use of PrEP in antenatal and postnatal care services, it is an important new HIV prevention method to consider, particularly for high-burden settings where women remain at significant HIV risk. There are three scenarios for which PrEP may be considered among HIV-negative pregnant and breastfeeding women: 1. a woman taking PrEP who subsequently becomes pregnant and",
      "extractCut": true
    },
    {
      "id": "sec-006-prep-as-part-of-pmtct-in-settings-of-high-hiv-in",
      "number": null,
      "title": "PrEP as part of PMTCT in settings of high HIV incidence",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 10,
      "labelStart": "6",
      "labelEnd": "8",
      "words": 827,
      "summary": {
        "text": "Describes how PrEP can be added to comprehensive HIV prevention in antenatal and postnatal care where HIV incidence is high, setting out eight elements of such a package in a box. The elements include repeat testing, partner testing and referral, condoms, STI screening and risk counselling. It also discusses risk assessment tools while cautioning that they should not be used to deny PrEP to women who request it.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv incidence",
          "heading": true
        },
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "offer partner",
          "heading": false
        },
        {
          "term": "partner referral",
          "heading": false
        },
        {
          "term": "male partner",
          "heading": false
        },
        {
          "term": "hiv-negative women",
          "heading": false
        },
        {
          "term": "partner notification",
          "heading": false
        },
        {
          "term": "request prep",
          "heading": false
        }
      ],
      "extract": "For high burden settings and for populations with high HIV incidence in low burden settings, all HIV-negative women should be offered prevention interventions at antenatal and postnatal visits (Box 1). In addition, PrEP could be offered as part of an enhanced comprehensive HIV prevention approach in selected sites where women experience ongoing high HIV incidence. Note that the other elements described in Box 1",
      "extractCut": true
    },
    {
      "id": "sec-007-prep-for-safer-conception",
      "number": null,
      "title": "PrEP for safer conception",
      "level": 1,
      "pageStart": 10,
      "pageEnd": 11,
      "labelStart": "8",
      "labelEnd": "9",
      "words": 236,
      "summary": {
        "text": "Discusses offering PrEP for safer conception to HIV-negative women whose partners have unknown status or are not virally suppressed, stressing that the decision rests with the woman. A Kenyan risk assessment scoring tool for pregnant women is shown as an example.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "male partner",
          "heading": false
        },
        {
          "term": "hiv risk",
          "heading": false
        },
        {
          "term": "hiv status",
          "heading": false
        },
        {
          "term": "hiv transmission",
          "heading": false
        },
        {
          "term": "woman",
          "heading": false
        },
        {
          "term": "rpr",
          "heading": false
        },
        {
          "term": "risk assessment",
          "heading": false
        }
      ],
      "extract": "HIV-negative women in high prevalence settings remain at high HIV risk during the period of conception when their partners are of unknown status, or their partners are living with HIV and are either (a) not on ART or (b) are not virally suppressed (including partners recently starting ART, whose full viral suppression may take up to six months). Offering PrEP during this time could decrease the risk of viral",
      "extractCut": true
    },
    {
      "id": "sec-008-monitoring-prep-use-by-pregnant-and-breastfeedin",
      "number": null,
      "title": "Monitoring PrEP use by pregnant and breastfeeding women",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 12,
      "labelStart": "9",
      "labelEnd": "10",
      "words": 384,
      "summary": {
        "text": "Sets out how mother and infant outcomes should be actively monitored when PrEP is used in pregnancy and breastfeeding, covering maternal toxicity, adverse birth outcomes and infant growth and development. It also suggests integrating PrEP indicators into existing drug toxicity surveillance and continuity of PrEP services.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "pregnant women",
          "heading": true
        },
        {
          "term": "arv toxicity",
          "heading": false
        },
        {
          "term": "breastfeeding",
          "heading": true
        },
        {
          "term": "during prep",
          "heading": false
        },
        {
          "term": "toxicity surveillance",
          "heading": false
        },
        {
          "term": "monitoring toxicity",
          "heading": false
        },
        {
          "term": "active toxicity",
          "heading": false
        }
      ],
      "extract": "Although the currently available data are reassuring regarding the safety of PrEP during pregnancy and breastfeeding, active surveillance of mother and infant outcomes during PrEP use in pregnancy and breastfeeding should be part of a PrEP programme. WHO currently recommends1 that the active surveillance of ARV drug toxicity during pregnancy and the breastfeeding period focus on three areas. These three areas should",
      "extractCut": true
    },
    {
      "id": "sec-009-summary-of-issues-and-considerations",
      "number": null,
      "title": "Summary of issues and considerations",
      "level": 2,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 252,
      "summary": {
        "text": "A summary table of issues and considerations for PrEP use, covering pregnancy and breastfeeding, desire to conceive, family planning, gender-based violence, sex workers and adolescent girls.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv-negative women",
          "heading": false
        },
        {
          "term": "gender-based violence",
          "heading": false
        },
        {
          "term": "prep",
          "heading": false
        },
        {
          "term": "substantial risk",
          "heading": false
        },
        {
          "term": "sex workers",
          "heading": false
        },
        {
          "term": "pregnancy",
          "heading": false
        },
        {
          "term": "breastfeeding",
          "heading": false
        },
        {
          "term": "health services",
          "heading": false
        }
      ],
      "extract": "Issues Considerations Pregnancy and breastfeeding PrEP can be started or continued during pregnancy and breastfeeding in women at substantial risk of HIV acquisition. A range of interventions should be offered to HIV-negative women in pregnancy and breastfeeding to prevent and detect incident HIV. These include condom promotion, counselling to reduce risk, risk assessment, STI screening and treatment, partner",
      "extractCut": true
    },
    {
      "id": "sec-010-key-messages",
      "number": null,
      "title": "Key messages",
      "level": 1,
      "pageStart": 12,
      "pageEnd": 13,
      "labelStart": "10",
      "labelEnd": "11",
      "words": 369,
      "summary": {
        "text": "Lists key messages of the brief, including that PrEP is safe in pregnancy and breastfeeding, should be part of a comprehensive prevention package, and depends on adherence. It also covers disclosure, changing periods of risk, compatibility with hormonal contraception and cost-effectiveness.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hormonal contraception",
          "heading": false
        },
        {
          "term": "breastfeeding women",
          "heading": false
        },
        {
          "term": "prep",
          "heading": false
        },
        {
          "term": "hiv risk",
          "heading": false
        },
        {
          "term": "hiv acquisition",
          "heading": false
        },
        {
          "term": "some women",
          "heading": false
        },
        {
          "term": "during pregnancy",
          "heading": false
        },
        {
          "term": "arvs",
          "heading": false
        }
      ],
      "extract": "• PrEP is safe during pregnancy and breastfeeding. The ARVs used for PrEP, TDF and TDF/FTC, are frequently used in combination with other ARVs for HIV treatment. The latest WHO systematic review suggests that there does not appear to be a safety-related rationale for disallowing or discontinuing PrEP during pregnancy and breastfeeding for HIV- negative women who are at continuing risk of HIV acquisition. • PrEP",
      "extractCut": true
    },
    {
      "id": "sec-011-references",
      "number": null,
      "title": "References",
      "level": 2,
      "pageStart": 13,
      "pageEnd": 16,
      "labelStart": "11",
      "labelEnd": "14",
      "words": 661,
      "summary": {
        "text": "The reference list for the technical brief on PrEP in pregnancy and breastfeeding, citing WHO HIV guidelines and studies on TDF safety and HIV risk in pregnant women, followed by WHO HIV department contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pre-exposure prophylaxis",
          "heading": false
        },
        {
          "term": "hiv acquisition",
          "heading": false
        },
        {
          "term": "during pregnancy",
          "heading": false
        },
        {
          "term": "defic syndr",
          "heading": false
        },
        {
          "term": "incident hiv",
          "heading": false
        },
        {
          "term": "sexual behavior",
          "heading": false
        },
        {
          "term": "acquir immune",
          "heading": false
        },
        {
          "term": "drake",
          "heading": false
        }
      ],
      "extract": "1. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015, Geneva: World Health Organization (http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/) 2. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV pre-exposure prophylaxis for all populations. AIDS. 2016 Jul 31; 30(12):1973–83. 3. Consolidated",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 0,
        "items": []
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "during prep",
      "heading": true
    },
    {
      "term": "breastfeeding women",
      "heading": true
    },
    {
      "term": "pregnant women",
      "heading": true
    },
    {
      "term": "prep safety",
      "heading": true
    },
    {
      "term": "prep services",
      "heading": false
    },
    {
      "term": "prep among",
      "heading": false
    },
    {
      "term": "prep regimens",
      "heading": false
    },
    {
      "term": "offering prep",
      "heading": true
    },
    {
      "term": "oral prep",
      "heading": false
    },
    {
      "term": "continue prep",
      "heading": false
    },
    {
      "term": "continuing prep",
      "heading": false
    },
    {
      "term": "receiving prep",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "a",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "b",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "1",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 4,
      "label": "2",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 5,
      "label": "3",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 6,
      "label": "4",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 7,
      "label": "5",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 8,
      "label": "6",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 9,
      "label": "7",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "8",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 11,
      "label": "9",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 12,
      "label": "10",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 13,
      "label": "11",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 14,
      "label": "12",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 15,
      "label": "13",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 16,
      "label": "14",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "figure",
      "number": "1",
      "title": "Women may be at increased risk of acquiring HIV during pregnancy, breastfeeding and the postpartum period",
      "page": 5,
      "pageLabel": "3",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "1",
      "title": "Eight elements of comprehensive HIV prevention in antenatal and postnatal care settings where HIV",
      "page": 8,
      "pageLabel": "6",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "2",
      "title": "A suggested prioritization framework for offering PrEP to pregnant and breastfeeding women (4)",
      "page": 9,
      "pageLabel": "7",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "3",
      "title": "Kenyan risk assessment scoring tool",
      "page": 10,
      "pageLabel": "8",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    }
  ],
  "images": [
    {
      "id": "img-p001-1",
      "file": "images/img-p001-1.webp",
      "page": 1,
      "narratives": {
        "en": "Cover photograph of a line of smiling women standing on grass outside a brick building with a solar panel on its roof, most of them holding babies or young children.",
        "ar": "صورة الغلاف لصف من النساء المبتسمات يقفن على العشب أمام مبنى من الطوب على سطحه لوح شمسي، وتحمل معظمهن رُضّعاً أو أطفالاً صغاراً.",
        "zh": "封面照片：一排面带微笑的妇女站在一栋屋顶装有太阳能板的砖砌建筑外的草地上，大多数人怀抱婴儿或幼儿。",
        "es": "Fotografía de portada de una fila de mujeres sonrientes de pie sobre el césped frente a un edificio de ladrillo con un panel solar en el tejado; la mayoría sostiene a bebés o niños pequeños.",
        "fr": "Photographie de couverture d'une rangée de femmes souriantes debout sur l'herbe devant un bâtiment en briques doté d'un panneau solaire sur le toit ; la plupart portent des bébés ou de jeunes enfants.",
        "ru": "Фотография на обложке: ряд улыбающихся женщин стоит на траве у кирпичного здания с солнечной панелью на крыше; большинство из них держат на руках младенцев или маленьких детей."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p005",
      "file": "figures/vfig-p005.webp",
      "page": 5,
      "shows": [
        "Figure 1"
      ],
      "narratives": {
        "en": "Page render with the 2015 WHO recommendation on PrEP (oral PrEP containing TDF should be offered as an additional prevention choice for people at substantial risk of HIV infection; high quality evidence, strong recommendation), a text section on why to offer PrEP to pregnant and breastfeeding women, and Figure 1, 'Women may be at increased risk of acquiring HIV during pregnancy, breastfeeding and the postpartum period'. The diagram links 'Biological Suseptibility' [sic] to elevated hormonal levels, untreated STIs and vaginal microbiome changes associated with cervical or genital inflammation, and nutritional deficiency and lowered immunity; 'Behavioural exposure' links to behaviour changes in women and male partners during the pregnancy/postpartum period. The figure is cut off at the bottom.",
        "ar": "صفحة مُصوَّرة تتضمن توصية منظمة الصحة العالمية لعام 2015 بشأن الوقاية قبل التعرض (PrEP) (ينبغي تقديم الوقاية الفموية قبل التعرض المحتوية على TDF كخيار وقائي إضافي للأشخاص المعرضين لخطر كبير للعدوى بفيروس العوز المناعي البشري؛ بيّنات عالية الجودة، توصية قوية)، وقسماً نصياً عن أسباب تقديم الوقاية قبل التعرض للحوامل والمرضعات، والشكل 1 «قد تكون النساء أكثر عرضة لخطر الإصابة بفيروس العوز المناعي البشري أثناء الحمل والرضاعة الطبيعية وفترة ما بعد الولادة». يربط المخطط «القابلية البيولوجية» بارتفاع المستويات الهرمونية، والعدوى المنقولة جنسياً غير المعالجة، وتغيرات الميكروبيوم المهبلي المرتبطة بالتهاب عنق الرحم أو الالتهاب التناسلي، ونقص التغذية وضعف المناعة؛ ويربط «التعرض السلوكي» بالتغيرات السلوكية لدى النساء وشركائهن الذكور خلال فترة الحمل/ما بعد الولادة. والشكل مقطوع من الأسفل.",
        "zh": "页面渲染图，包含2015年世卫组织关于暴露前预防（PrEP）的建议（应向艾滋病毒感染重大风险人群提供含TDF的口服PrEP，作为综合预防方法中的额外预防选择；高质量证据，强推荐）、关于为何向孕妇和哺乳期妇女提供PrEP的文字部分，以及图1“妇女在妊娠、哺乳和产后期间感染艾滋病毒的风险可能增加”。该图将“生物易感性”（原文拼写为Suseptibility）与激素水平升高、未经治疗的性传播感染、与宫颈或生殖器炎症相关的阴道微生物组变化以及营养缺乏和免疫力下降相联系；“行为暴露”则与妇女及其男性伴侣在妊娠/产后期间的行为变化相联系。该图底部被截断。",
        "es": "Imagen de página con la recomendación de la OMS de 2015 sobre la PrEP (debe ofrecerse PrEP oral con TDF como opción de prevención adicional a las personas con riesgo sustancial de infección por el VIH; evidencia de alta calidad, recomendación firme), una sección de texto sobre por qué ofrecer PrEP a mujeres embarazadas y lactantes, y la figura 1, «Las mujeres pueden tener mayor riesgo de contraer el VIH durante el embarazo, la lactancia y el puerperio». El diagrama vincula la «Biological Suseptibility» [sic] con niveles hormonales elevados, ITS no tratadas y cambios del microbioma vaginal asociados a inflamación cervical o genital, y con deficiencias nutricionales e inmunidad reducida; la «exposición conductual» se vincula con cambios de comportamiento de las mujeres y sus parejas masculinas durante el embarazo y el puerperio. La figura está cortada en la parte inferior.",
        "fr": "Rendu de page comportant la recommandation de l'OMS de 2015 sur la PrEP (la PrEP orale contenant du TDF doit être proposée comme choix de prévention supplémentaire aux personnes exposées à un risque substantiel d'infection à VIH ; données de haute qualité, recommandation forte), une section de texte expliquant pourquoi proposer la PrEP aux femmes enceintes et allaitantes, et la figure 1, « Les femmes peuvent être exposées à un risque accru de contracter le VIH pendant la grossesse, l'allaitement et le post-partum ». Le schéma relie la « Biological Suseptibility » [sic] à des taux hormonaux élevés, à des IST non traitées et à des modifications du microbiome vaginal associées à une inflammation cervicale ou génitale, ainsi qu'aux carences nutritionnelles et à une immunité réduite ; l'« exposition comportementale » est reliée aux changements de comportement des femmes et de leurs partenaires masculins pendant la grossesse et le post-partum. La figure est coupée en bas.",
        "ru": "Изображение страницы с рекомендацией ВОЗ 2015 г. по ДКП (пероральную ДКП, содержащую TDF, следует предлагать в качестве дополнительного средства профилактики людям со значительным риском ВИЧ-инфекции; доказательства высокого качества, сильная рекомендация), текстовым разделом о том, зачем предлагать ДКП беременным и кормящим грудью женщинам, и рисунком 1 «Женщины могут подвергаться повышенному риску заражения ВИЧ во время беременности, грудного вскармливания и в послеродовой период». Схема связывает «биологическую восприимчивость» (в оригинале с опечаткой Suseptibility) с повышенным уровнем гормонов, нелеченными ИППП и изменениями микробиома влагалища, связанными с воспалением шейки матки или половых органов, а также с недостаточностью питания и сниженным иммунитетом; «поведенческое воздействие» связано с изменениями поведения женщин и их партнеров-мужчин в период беременности и после родов. Рисунок обрезан снизу."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p009",
      "file": "figures/vfig-p009.webp",
      "page": 9,
      "shows": [
        "Figure 2"
      ],
      "narratives": {
        "en": "Flowchart of a suggested prioritization framework for offering PrEP to pregnant and breastfeeding women (Figure 2). From antenatal registration with provider-initiated HIV testing and counselling, HIV-positive women receive PMTCT, treatment, support and partner notification; HIV-negative women receive post-test counselling, partner testing and a risk assessment using a tool. A partner who is HIV-negative leads to reassessing the woman's risk and referring the partner for VMMC; a partner not tested or HIV-positive, or a positive risk assessment, identifies a woman at substantial risk, who is offered comprehensive prevention (STI screening and treatment, condoms, risk reduction counselling, PrEP with emphasis on adherence, follow-up ANC visits). A woman who chooses to initiate PrEP receives clinical and laboratory assessments, adherence counselling and repeat HIV testing.",
        "ar": "مخطط انسيابي لإطار مقترح لتحديد أولويات تقديم الوقاية قبل التعرض للحوامل والمرضعات (الشكل 2). بدءاً من التسجيل في رعاية ما قبل الولادة مع اختبار فيروس العوز المناعي البشري والمشورة بمبادرة من مقدم الخدمة، تتلقى النساء المصابات بالفيروس خدمات الوقاية من انتقال الفيروس من الأم إلى الطفل والعلاج والدعم وإخطار الشريك؛ وتتلقى النساء غير المصابات المشورة بعد الاختبار واختبار الشريك وتقييماً للخطر باستخدام أداة. إذا كان الشريك غير مصاب يُعاد تقييم خطر المرأة ويُحال الشريك إلى الختان الطبي الطوعي للذكور؛ وإذا لم يُختبر الشريك أو كان مصاباً، أو أظهر تقييم الخطر خطراً كبيراً، تُعدّ المرأة معرضة لخطر كبير وتُقدَّم لها خيارات وقاية شاملة (تحرّي العدوى المنقولة جنسياً وعلاجها، والعوازل، ومشورة الحد من المخاطر، والوقاية قبل التعرض مع التأكيد على الالتزام، وزيارات المتابعة في رعاية ما قبل الولادة). وتتلقى المرأة التي تختار بدء الوقاية قبل التعرض تقييمات سريرية ومختبرية ومشورة بشأن الالتزام وتكرار اختبار الفيروس.",
        "zh": "向孕妇和哺乳期妇女提供PrEP的建议优先排序框架流程图（图2）。从产前登记及医务人员主动提供的艾滋病毒检测和咨询开始，艾滋病毒阳性妇女接受预防母婴传播、治疗、支持和性伴告知服务；艾滋病毒阴性妇女接受检测后咨询、性伴检测以及使用工具进行的风险评估。性伴为阴性时，重新评估妇女风险并转介性伴接受自愿男性包皮环切；性伴未检测或为阳性，或风险评估显示风险重大时，该妇女被视为有重大风险，并获得综合预防服务（性传播感染筛查和治疗、安全套推广、降低风险咨询、强调依从性的PrEP、产前随访）。选择开始PrEP的妇女接受临床和实验室评估、依从性咨询以及重复艾滋病毒检测。",
        "es": "Diagrama de flujo de un marco de priorización propuesto para ofrecer la PrEP a mujeres embarazadas y lactantes (figura 2). Desde el registro prenatal con pruebas y asesoramiento sobre el VIH iniciados por el proveedor, las mujeres con VIH reciben PTMI, tratamiento, apoyo y notificación a la pareja; las mujeres VIH-negativas reciben asesoramiento posterior a la prueba, pruebas a la pareja y una evaluación del riesgo con una herramienta. Si la pareja es VIH-negativa, se reevalúa el riesgo de la mujer y se deriva a la pareja a CMMV; si la pareja no se ha hecho la prueba o es VIH-positiva, o la evaluación indica riesgo sustancial, la mujer se considera en riesgo sustancial y se le ofrece prevención integral (cribado y tratamiento de ITS, preservativos, asesoramiento para reducir riesgos, PrEP con énfasis en la adherencia, visitas prenatales de seguimiento). La mujer que decide iniciar la PrEP recibe evaluaciones clínicas y de laboratorio, asesoramiento sobre adherencia y repetición de la prueba del VIH.",
        "fr": "Logigramme d'un cadre de priorisation proposé pour offrir la PrEP aux femmes enceintes et allaitantes (figure 2). À partir de l'inscription prénatale avec dépistage du VIH et conseil à l'initiative du soignant, les femmes séropositives reçoivent la PTME, un traitement, un soutien et la notification au partenaire ; les femmes séronégatives reçoivent des conseils post-test, un dépistage du partenaire et une évaluation du risque à l'aide d'un outil. Si le partenaire est séronégatif, le risque de la femme est réévalué et le partenaire est orienté vers la CMMV ; si le partenaire n'est pas dépisté ou est séropositif, ou si l'évaluation montre un risque substantiel, la femme est considérée à risque substantiel et se voit proposer une prévention complète (dépistage et traitement des IST, préservatifs, conseils de réduction des risques, PrEP en insistant sur l'observance, visites prénatales de suivi). La femme qui choisit de commencer la PrEP bénéficie d'évaluations cliniques et biologiques, de conseils sur l'observance et d'un nouveau dépistage du VIH.",
        "ru": "Блок-схема предлагаемой системы определения приоритетов при предложении ДКП беременным и кормящим грудью женщинам (рисунок 2). После постановки на учет в женской консультации с тестированием на ВИЧ и консультированием по инициативе медработника ВИЧ-положительные женщины получают услуги по ППМР, лечение, поддержку и уведомление партнера; ВИЧ-отрицательные женщины получают послетестовое консультирование, тестирование партнера и оценку риска с помощью инструмента. Если партнер ВИЧ-отрицателен, риск женщины оценивается повторно, а партнера направляют на ДМОМ; если партнер не тестировался или ВИЧ-положителен либо оценка выявляет значительный риск, женщина считается подверженной значительному риску и ей предлагается комплексная профилактика (скрининг и лечение ИППП, презервативы, консультирование по снижению риска, ДКП с акцентом на приверженность, последующие дородовые визиты). Женщина, решившая начать ДКП, проходит клиническое и лабораторное обследование, консультирование по приверженности и повторное тестирование на ВИЧ."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p010",
      "file": "figures/vfig-p010.webp",
      "page": 10,
      "shows": [
        "Figure 3"
      ],
      "narratives": {
        "en": "Page render including Figure 3, 'Kenyan risk assessment scoring tool' (source: Pintye et al, 2016): a table of risk factors with value per factor and blank columns for complete and simplified scores – number of lifetime sexual partners (1 point per partner, enter at least 1); male partner HIV status (known or no partner 0, unknown 6); syphilis (RPR nonreactive 0, reactive 5); bacterial vaginosis (negative or not screened 0, positive 2); candidiasis (negative or not screened 0, positive 3); and a total risk score row. Surrounding text and two callout boxes on HIV risk assessment tools and PrEP for women trying to conceive are partly cut off at the left.",
        "ar": "صفحة مُصوَّرة تتضمن الشكل 3 «أداة تسجيل درجات تقييم المخاطر الكينية» (المصدر: Pintye et al، 2016): جدول لعوامل الخطر مع القيمة لكل عامل وأعمدة فارغة للدرجة الكاملة والدرجة المبسّطة – عدد الشركاء الجنسيين مدى الحياة (نقطة واحدة لكل شريك، أدخل 1 على الأقل)؛ وحالة الشريك الذكر من حيث فيروس العوز المناعي البشري (معروفة أو لا يوجد شريك 0، غير معروفة 6)؛ والزهري (RPR غير متفاعل 0، متفاعل 5)؛ والتهاب المهبل الجرثومي (سلبي أو لم يُتحرَّ 0، إيجابي 2)؛ وداء المبيضات (سلبي أو لم يُتحرَّ 0، إيجابي 3)؛ وصف لمجموع درجات الخطر. والنص المحيط وإطاران توضيحيان عن أدوات تقييم خطر الفيروس والوقاية قبل التعرض للنساء الساعيات إلى الحمل مقطوعة جزئياً من اليسار.",
        "zh": "页面渲染图，包含图3“肯尼亚风险评估评分工具”（来源：Pintye等，2016）：列出风险因素及每项分值，并留有完整评分和简化评分空白栏——终身性伴数（每个性伴1分，至少填1）；男性伴侣艾滋病毒状况（已知或无男性伴侣0分，未知6分）；梅毒（RPR无反应0分，有反应5分）；细菌性阴道病（阴性或未筛查0分，阳性2分）；念珠菌病（阴性或未筛查0分，阳性3分）；以及风险总分行。周围文字以及关于艾滋病毒风险评估工具和为备孕妇女提供PrEP的两个提示框左侧部分被截去。",
        "es": "Imagen de página que incluye la figura 3, «Herramienta keniana de puntuación para la evaluación del riesgo» (fuente: Pintye et al., 2016): una tabla de factores de riesgo con el valor por factor y columnas vacías para la puntuación completa y la simplificada: número de parejas sexuales a lo largo de la vida (1 punto por pareja, indicar al menos 1); estado serológico de la pareja masculina (conocido o sin pareja 0, desconocido 6); sífilis (RPR no reactiva 0, reactiva 5); vaginosis bacteriana (negativa o no cribada 0, positiva 2); candidiasis (negativa o no cribada 0, positiva 3); y una fila de puntuación total del riesgo. El texto circundante y dos recuadros sobre herramientas de evaluación del riesgo de VIH y sobre la PrEP para mujeres que intentan concebir están parcialmente cortados a la izquierda.",
        "fr": "Rendu de page comprenant la figure 3, « Outil kényan de notation pour l'évaluation du risque » (source : Pintye et al., 2016) : un tableau des facteurs de risque avec la valeur par facteur et des colonnes vides pour le score complet et le score simplifié – nombre de partenaires sexuels au cours de la vie (1 point par partenaire, inscrire au moins 1) ; statut VIH du partenaire masculin (connu ou pas de partenaire 0, inconnu 6) ; syphilis (RPR non réactif 0, réactif 5) ; vaginose bactérienne (négative ou non dépistée 0, positive 2) ; candidose (négative ou non dépistée 0, positive 3) ; et une ligne de score de risque total. Le texte environnant et deux encadrés sur les outils d'évaluation du risque de VIH et sur la PrEP pour les femmes qui souhaitent concevoir sont partiellement coupés à gauche.",
        "ru": "Изображение страницы с рисунком 3 «Кенийский инструмент балльной оценки риска» (источник: Pintye et al, 2016): таблица факторов риска со значением для каждого фактора и пустыми столбцами для полного и упрощенного балла — число половых партнеров за всю жизнь (1 балл за партнера, указать не менее 1); ВИЧ-статус партнера-мужчины (известен или партнера нет — 0, неизвестен — 6); сифилис (RPR нереактивный — 0, реактивный — 5); бактериальный вагиноз (отрицательный или скрининг не проводился — 0, положительный — 2); кандидоз (отрицательный или скрининг не проводился — 0, положительный — 3); строка общего балла риска. Окружающий текст и две выноски об инструментах оценки риска ВИЧ и о ДКП для женщин, пытающихся забеременеть, частично обрезаны слева."
      },
      "state": "draft"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 12,
      "note": "outline"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 13,
      "note": "2 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 4
    },
    {
      "kind": "tables",
      "state": "not-extracted"
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p13); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "found",
      "count": 13,
      "note": "13 of 13 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-255866"
  }
}
